Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...

The company is one of a handful developing a more “selective” URAT1 inhibitor, an approach that’s seen as a way to improve ...